Conclusions

  • Analyses of gene expression levels in the INSTAGE trial identified a small number of genes that were downregulated after 24 weeks’ treatment with nintedanib plus sildenafil or nintedanib alone in subjects with IPF and severely impaired gas exchange.
  • Some of the genes downregulated in patients treated with nintedanib in the INMARK trial were also found to be downregulated in patients treated with nintedanib plus sildenafil in the INSTAGE trial.
  • The potential of gene expression profiling as a marker of treatment response in patients with IPF requires further study.
Header - Navigation Icon